Search

Displaying results 851 - 860 of 4233 in total
  1. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities such as hypertension, diabetes, and depression. … Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia.

  2. Drug

    Lanreotide

    go.drugbank.com/drugs/DB06791
    ApprovedInvestigational

    Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_.

  3. Drug

    2-deoxyglucose

    go.drugbank.com/drugs/DB08831
    Investigational

    2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel). … As an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy.

  4. Drug

    Histidine

    go.drugbank.com/drugs/DB00117
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is required for the production of histamine.

  5. Drug

    Dactinomycin

    go.drugbank.com/drugs/DB00970
    ApprovedInvestigational

    As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

  6. Drug

    Levamisole

    go.drugbank.com/drugs/DB00848
    ApprovedInvestigationalVet approvedWithdrawn

    [A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. … [L6232] Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis.

  7. Drug

    Cariprazine

    go.drugbank.com/drugs/DB06016
    ApprovedInvestigational

    [A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022.

  8. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    [L54638] Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR).

  9. Drug

    Chlorobutanol

    go.drugbank.com/drugs/DB11386
    ApprovedVet approvedWithdrawn

    As a long-term stabilizer of multi-ingredient preparations, chlorobutanol is normally used at a concentration of 0.5%. At this concentration, it also conserves its antimicrobial activity. … Due to the long terminal half-life of 37 days, the use of chlorobutanol as a sedative is limited because of the considerable accumulation which will occur following multiple dosing [A32743].

  10. Drug

    Carboxymethylcellulose

    go.drugbank.com/drugs/DB11059
    ApprovedInvestigational

    It is added in food products as a viscosity modifier or thickener and emulsifier. … The viscous and mucoadhesive properties as well as its anionic charge allow prolonged retention time in the ocular surface [A33029]. Sodium carboxymethylcellulose is the most commonly used salt.